Article Sidebar

PDF
Date Published: 28/12/2022
Abstract Views: 220
Views PDF: 277
DOI: https://doi.org/10.51298/vmj.v520i1A.3798
Issue
Vol. 520 No. 1A (2022)
Section
Các bài báo
How to Cite
Thị Dùng, N. ., Vinh Quang, B. ., & Văn Hiếu, N. . (2022). INITIAL OUTCOME OF USING PEMBROLIZUMB- A PD-1 RECEPTOR BLOKING ANTIBODY AS THE SECOND-LINE TREATMENT FOR PATIENTS WITH PRIMARY HEPATOCELLULAR CARCINOMA. Vietnam Medical Journal, 520(1A). https://doi.org/10.51298/vmj.v520i1A.3798

INITIAL OUTCOME OF USING PEMBROLIZUMB- A PD-1 RECEPTOR BLOKING ANTIBODY AS THE SECOND-LINE TREATMENT FOR PATIENTS WITH PRIMARY HEPATOCELLULAR CARCINOMA

Nguyễn Thị Dùng1,, Bùi Vinh Quang1, Nguyễn Văn Hiếu2
1 Hanoi Oncology Hospital
2 Hanoi Medical University

Main Article Content

Abstract

Purpose: To evaluate the second-line treatment outcome of pembrolizumab on patients with primary hepatocellular carcinoma (HCC). Subjects and research methods: The study was designed as an uncontrolled clinically interventional study on primary HCC patients taken pembrolizumab in second-line treatment at Hanoi Oncology Hospital (HOH) and Vietnam National Cancer Hospital from January 1, 2020 to June 30, 2022. Results: In a total of 35 patients participating in the study,17.1% of them had partial response, 42.9% had stable disease, 40% had progressive cancer and the disease control rate was 60%. Progression-free survival was 3.1 months. Conclusion: Using Pembrolizumab in second-line treatment for primary HCC patients is shown to be quite effective, providing survival benefits for patients.

Article Details

Keywords

Hepatocellular carcinoma (HCC), Pembrolizumab, second-line, response, Hanoi Ongcology Hospital, Vietnam National Cancer Hospital

References

1. SUNG, Hyuna, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, 2021, 71.3: 209-249.
2. LLOVET, Josep M.; FUSTER, Josep; BRUIX, Jordi. Intention‐to‐treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology, 1999, 30.6: 1434-1440.
3. LIN, Zhong-Zhe, et al. Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size. PLoS One, 2013, 8.11: e80276.
4. CHOW, P. K., et al. Asia-Pacific Hepatocellular Carcinoma Trials Group SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma. J Clin Oncol, 2018, 36: 1913-1921.
5. CHENG, Ann-Lii, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. The lancet oncology, 2009, 10.1: 25-34.
6. LLOVET, Josep M., et al. Sorafenib in advanced hepatocellular carcinoma. New England journal of medicine, 2008, 359.4: 378-390.
7. KUDO, Masatoshi, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. The Lancet, 2018, 391.10126: 1163-1173.
8. ZHU, Andrew X., et al. KEYNOTE-224: Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib. 2018.
9. FINN, Richard S., et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. 2020.